LGND vs. EPD

Last updated Jun 3, 2026

LGND (Ligand Pharmaceuticals Incorporated) and EPD (Enterprise Products Partners L.P.) are both stocks. LGND operates in Biotechnology (Healthcare), while EPD operates in Oil & Gas Midstream (Energy). Over the past 10 years, LGND returned 7.02%/yr vs 10.46%/yr for EPD. At a 0.16 correlation, their price movements are largely independent.

Performance

LGND vs. EPD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ligand Pharmaceuticals Incorporated (LGND) and Enterprise Products Partners L.P. (EPD). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LGND achieves a 23.11% return, which is significantly higher than EPD's 21.27% return. Over the past 10 years, LGND has underperformed EPD with an annualized return of 7.02%, while EPD has yielded a comparatively higher 10.46% annualized return.

LGND

• 1D: 1.30%
• 1M: 2.34%
• YTD: 23.11%
• 6M: 19.30%
• 1Y: 129.00%
• 3Y*: 45.66%
• 5Y*: 15.54%
• 10Y*: 7.02%

EPD

• 1D: 1.34%
• 1M: -0.84%
• YTD: 21.27%
• 6M: 21.54%
• 1Y: 29.66%
• 3Y*: 21.47%
• 5Y*: 17.41%
• 10Y*: 10.46%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LGND vs. EPD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LGND Ligand Pharmaceuticals Incorporated	23.11%	76.45%	50.03%	6.92%	-56.75%	55.31%	-4.64%	-23.15%	-0.90%	34.76%
EPD Enterprise Products Partners L.P.	21.27%	9.45%	28.00%	17.71%	18.32%	21.40%	-23.61%	21.88%	-1.32%	4.24%

Correlation

The correlation between LGND and EPD is -0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.00
Correlation (3Y) Calculated over the trailing 3-year period	0.10
Correlation (5Y) Calculated over the trailing 5-year period	0.14
Correlation (10Y) Calculated over the trailing 10-year period	0.18
Correlation (All Time) Calculated using the full available price history since Jul 29, 1998	0.16

The correlation between LGND and EPD shifts across timeframes, from -0.00 (1 year) to 0.18 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap LGND : $4.63B EPD : $82.47B
EPS LGND : $7.57 EPD : $2.69
PE Ratio LGND : 30.74 EPD : 14.00
PEG Ratio LGND : 0.26 EPD : 2.25
PS Ratio LGND : 17.20 EPD : 1.60
Total Revenue (TTM) LGND : $274.48M EPD : $51.57B
Gross Profit (TTM) LGND : $221.02M EPD : $7.31B
EBITDA (TTM) LGND : $253.90M EPD : $10.11B

Return for Risk

LGND vs. EPD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LGND

LGND Risk / Return Rank: 95
LGND Sharpe Ratio Rank: 96
LGND Sortino Ratio Rank: 94
LGND Omega Ratio Rank: 93
LGND Calmar Ratio Rank: 97
LGND Martin Ratio Rank: 96

EPD

EPD Risk / Return Rank: 86
EPD Sharpe Ratio Rank: 86
EPD Sortino Ratio Rank: 84
EPD Omega Ratio Rank: 82
EPD Calmar Ratio Rank: 87
EPD Martin Ratio Rank: 90

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LGND vs. EPD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and Enterprise Products Partners L.P. (EPD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LGND	EPD	Difference
Sharpe ratio Return per unit of total volatility	3.53	1.87	+1.67
Sortino ratio Return per unit of downside risk	3.92	2.64	+1.28
Omega ratio Gain probability vs. loss probability	1.52	1.33	+0.19
Calmar ratio Return relative to maximum drawdown	9.08	4.05	+5.03
Martin ratio Return relative to average drawdown	22.93	12.67	+10.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LGND vs. EPD - Sharpe Ratio Comparison

The current LGND Sharpe Ratio is 3.53, which is higher than the EPD Sharpe Ratio of 1.87. The chart below compares the historical Sharpe Ratios of LGND and EPD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	LGND	EPD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.53	1.87	+1.67
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.35	1.02	-0.66
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.16	0.43	-0.28
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	0.54	-0.43

Drawdowns

LGND vs. EPD - Drawdown Comparison

The maximum LGND drawdown since its inception was -93.34%, which is greater than EPD's maximum drawdown of -58.78%. Use the drawdown chart below to compare losses from any high point for LGND and EPD.

Drawdown Indicators

	LGND	EPD	Difference
Max Drawdown Largest peak-to-trough decline	-93.34%	-58.78%	-34.56%
Max Drawdown (1Y) Largest decline over 1 year	-14.07%	-7.56%	-6.51%
Max Drawdown (3Y) Largest decline over 3 years	-37.25%	-15.40%	-21.85%
Max Drawdown (5Y) Largest decline over 5 years	-70.11%	-18.06%	-52.05%
Max Drawdown (10Y) Largest decline over 10 years	-81.94%	-58.04%	-23.90%
Current Drawdown Current decline from peak	-15.20%	-5.25%	-9.95%
Average Drawdown Average peak-to-trough decline	-44.58%	-10.13%	-34.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.57%	2.42%	+3.15%

Volatility

LGND vs. EPD - Volatility Comparison

Ligand Pharmaceuticals Incorporated (LGND) has a higher volatility of 14.21% compared to Enterprise Products Partners L.P. (EPD) at 6.74%. This indicates that LGND's price experiences larger fluctuations and is considered to be riskier than EPD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LGND	EPD	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.21%	6.74%	+7.47%
Volatility (6M) Calculated over the trailing 6-month period	28.00%	13.29%	+14.71%
Volatility (1Y) Calculated over the trailing 1-year period	36.73%	15.98%	+20.75%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	44.07%	17.23%	+26.84%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	45.39%	24.16%	+21.23%

Dividends

LGND vs. EPD - Dividend Comparison

LGND has not paid dividends to shareholders, while EPD's dividend yield for the trailing twelve months is around 5.81%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
EPD Enterprise Products Partners L.P.	5.81%	6.74%	6.63%	7.51%	7.79%	8.20%	9.09%	6.23%	6.97%	6.29%	5.88%	5.90%
LGND Ligand Pharmaceuticals Incorporated	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

LGND vs. EPD - Profitability Comparison

The chart below illustrates the profitability comparison between Ligand Pharmaceuticals Incorporated and Enterprise Products Partners L.P. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LGND - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported a gross profit of 0.00 and revenue of 51.72M. Therefore, the gross margin over that period was 0.0%.

EPD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Enterprise Products Partners L.P. reported a gross profit of 1.88B and revenue of 14.39B. Therefore, the gross margin over that period was 13.1%.

LGND - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported an operating income of 17.37M and revenue of 51.72M, resulting in an operating margin of 33.6%.

EPD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Enterprise Products Partners L.P. reported an operating income of 1.82B and revenue of 14.39B, resulting in an operating margin of 12.6%.

LGND - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ligand Pharmaceuticals Incorporated reported a net income of -13.35M and revenue of 51.72M, resulting in a net margin of -25.8%.

EPD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Enterprise Products Partners L.P. reported a net income of 1.48B and revenue of 14.39B, resulting in a net margin of 10.3%.

Frequently Asked Questions

Can I hold both LGND and EPD in my portfolio?

LGND and EPD have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LGND or EPD?

LGND has higher volatility (14.21%) compared to EPD (6.74%). In terms of maximum drawdown, LGND dropped -93.34% vs EPD's -58.78%.

Which has better risk-adjusted returns?

LGND currently has the higher Sharpe Ratio (3.53 vs 1.87), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.